What changed in this filing

/stocks — the workspaceLOADING

Item 5. Other Information

2024-02-14 compared with 2023-11-13 · 55 added, 18 removed, 18 unchanged (80% of the section changed)

Other Information.

the period covered by this Quarterly Report, none of the Company’s directors or executive officers has adopted or terminated a

Rule 10b5-1 trading arrangement or a non-Rule 10b5-1 trading arrangement (each as defined in Item 408 of Regulation S-K under the Securities

Exchange Act of 1934, as amended).

following exhibits are filed as part of, or incorporated by reference into, this Quarterly Report on Form 10-Q.

Amended and Restated Agreement and Plan of Merger, dated as of July 21, 2023, by and among the Company, DMAC Merger Sub Inc., Bright Vision Sponsor LLC, Christopher Jones and TruGolf, Inc.

(incorporated by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K filed on July 24, 2023)

Second Amendment to the Second Amended and Restated Certificate of Incorporation (incorporated by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K filed on July 14, 2023)

Form of Warrant (incorporated herein by reference to Exhibit 4.1 to the Company’s Current Report on Form 8-K filed with the SEC on November 2, 2023)

Form of Non-Redemption Agreement and Assignment of Economic Interest (incorporated herein by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed with the SEC on July 12, 2023)

Loan Agreement, dated as of November 2, 2023, by and between Deep Medicine Acquisition Corp.

Amendment to the Merger Agreement, dated as of December 7, 2023, by and among the Company, DMAC Merger Sub Inc., Bright Vision Sponsor

LLC, Christopher Jones and TruGolf, Inc.

(incorporated by reference to Exhibit 2.1 to the Company’s Current Report on Form

8-K filed on December 7, 2023)

of Warrant (incorporated herein by reference to Exhibit 4.1 to the Company’s Current Report on Form 8-K filed with the SEC

on November 2, 2023)

Agreement, dated as of November 2, 2023, by and between Deep Medicine Acquisition Corp.

and Greentree Financial Group, Inc.

(incorporated herein by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed with the SEC on November 2, 2023)

Loan Agreement, dated as of November 2, 2023, by and between Deep Medicine Acquisition Corp.

and Finuvia, LLC (incorporated herein by reference to Exhibit 10.2 to the Company’s Current Report on Form 8-K filed with the SEC on November 2, 2023)

Form of Registration Rights Agreement (incorporated herein by reference to Exhibit 10.3 to the Company’s Current Report on Form 8-K filed with the SEC on November 2, 2023)

Form of Convertible Note (incorporated herein by reference to Exhibit 10.4 to the Company’s Current Report on Form 8-K filed with the SEC on November 2, 2023)

Certification of Principal Executive Officer Pursuant to Securities Exchange Act Rules 13a-14(a) and 15(d)-14(a), as adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

Certification of Principal Financial Officer Pursuant to Securities Exchange Act Rules 13a-14(a) and 15(d)-14(a), as adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

Certification of Principal Executive Officer Pursuant to 18 U.S.C.

(incorporated

herein by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed with the SEC on November 2, 2023)

Agreement, dated as of November 2, 2023, by and between Deep Medicine Acquisition Corp.

and Finuvia, LLC (incorporated herein by

reference to Exhibit 10.2 to the Company’s Current Report on Form 8-K filed with the SEC on November 2, 2023)

of Registration Rights Agreement (incorporated herein by reference to Exhibit 10.3 to the Company’s Current Report on Form

8-K filed with the SEC on November 2, 2023)

of Convertible Note (incorporated herein by reference to Exhibit 10.4 to the Company’s Current Report on Form 8-K filed with

the SEC on November 2, 2023)

Agreement, dated as of December 7, 2023, by and between Deep Medicine Acquisition Corp.

and Li Holding, Inc.

(incorporated herein

by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed with the SEC on December 7, 2023)

Agreement, dated as of December 7, 2023, by and between Deep Medicine Acquisition Corp.

and L&H, Inc.

(incorporated herein by

reference to Exhibit 10.2 to the Company’s Current Report on Form 8-K filed with the SEC on December 7, 2023)

Agreement, dated as of December 7, 2023, by and between Deep Medicine Acquisition Corp.

and JAK Opportunities VI, LLC.

(incorporated

herein by reference to Exhibit 10.3 to the Company’s Current Report on Form 8-K filed with the SEC on December 7, 2023)

and Restated Loan Agreement, dated as of December 7, 2023, by and between Deep Medicine Acquisition Corp.

and Finuvia, LLC.

(incorporated

herein by reference to Exhibit 10.4 to the Company’s Current Report on Form 8-K filed with the SEC on December 7, 2023)

Certification

of Principal Executive Officer Pursuant to Securities Exchange Act Rules 13a-14(a) and 15(d)-14(a), as adopted Pursuant to Section

302 of the Sarbanes-Oxley Act of 2002

Certification

of Principal Financial Officer Pursuant to Securities Exchange Act Rules 13a-14(a) and 15(d)-14(a), as adopted Pursuant to Section

302 of the Sarbanes-Oxley Act of 2002

Certification

of Principal Executive Officer Pursuant to 18 U.S.C.

Section 1350, as adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of

Certification of Principal Financial Officer Pursuant to 18 U.S.C.

Certification

of Principal Financial Officer Pursuant to 18 U.S.C.

Section 1350, as adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of

6 unchanged sentences

Page Interactive Data File.

exhibits and schedules to this Exhibit have been omitted in accordance with Item 601(b)(2)

of Regulation S-K.

The Registrant agrees to furnish supplementally to the SEC a copy of all

omitted exhibits and schedules upon its request.

accordance with the requirements of the Securities Exchange Act of 1934, the registrant caused this report to be signed on its behalf

by the undersigned, thereunto duly authorized.

MEDICINE ACQUISITION CORP.

November 13, 2023

Holdings, Inc.

Deep Medicine Acquisition Corp.

February 14, 2024

Christopher Jones

Executive Officer

Executive Officer)

November 13, 2023

February 14, 2024

Lindsay Jones

Financial Officer

1 unchanged sentence

Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.

What changed 10-Q

Item 5. Other Information